Cara Therapeutic Stock Probability of Future Stock Price Finishing Over 0.29
| CARA Stock | USD 0.29 0.01 3.33% |
Cara |
Cara Therapeutic Target Price Odds to finish over 0.29
The tendency of Cara Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.29 | 90 days | 0.29 | about 62.97 |
Based on a normal probability distribution, the odds of Cara Therapeutic to move above the current price in 90 days from now is about 62.97 (This Cara Therapeutic probability density function shows the probability of Cara Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.12 suggesting Cara Therapeutic market returns are sensitive to returns on the market. As the market goes up or down, Cara Therapeutic is expected to follow. Additionally Cara Therapeutic has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Cara Therapeutic Price Density |
| Price |
Predictive Modules for Cara Therapeutic
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Cara Therapeutic. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Cara Therapeutic Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Cara Therapeutic is not an exception. The market had few large corrections towards the Cara Therapeutic's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Cara Therapeutic, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Cara Therapeutic within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.42 | |
β | Beta against Dow Jones | 1.12 | |
σ | Overall volatility | 0.03 | |
Ir | Information ratio | -0.09 |
Cara Therapeutic Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Cara Therapeutic for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Cara Therapeutic can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Cara Therapeutic generated a negative expected return over the last 90 days | |
| Cara Therapeutic has some characteristics of a very speculative penny stock | |
| Cara Therapeutic has high historical volatility and very poor performance | |
| Cara Therapeutic has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 20.97 M. Net Loss for the year was (118.51 M) with loss before overhead, payroll, taxes, and interest of (56.14 M). | |
| Cara Therapeutic currently holds about 157.51 M in cash with (92.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.93, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 16.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Cara Q3 Earnings Snapshot |
Cara Therapeutic Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Cara Stock often depends not only on the future outlook of the current and potential Cara Therapeutic's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cara Therapeutic's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 54.1 M | |
| Cash And Short Term Investments | 100.8 M |
Cara Therapeutic Technical Analysis
Cara Therapeutic's future price can be derived by breaking down and analyzing its technical indicators over time. Cara Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Cara Therapeutic. In general, you should focus on analyzing Cara Stock price patterns and their correlations with different microeconomic environments and drivers.
Cara Therapeutic Predictive Forecast Models
Cara Therapeutic's time-series forecasting models is one of many Cara Therapeutic's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Cara Therapeutic's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Cara Therapeutic
Checking the ongoing alerts about Cara Therapeutic for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Cara Therapeutic help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Cara Therapeutic generated a negative expected return over the last 90 days | |
| Cara Therapeutic has some characteristics of a very speculative penny stock | |
| Cara Therapeutic has high historical volatility and very poor performance | |
| Cara Therapeutic has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 20.97 M. Net Loss for the year was (118.51 M) with loss before overhead, payroll, taxes, and interest of (56.14 M). | |
| Cara Therapeutic currently holds about 157.51 M in cash with (92.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.93, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 16.0% of the company shares are held by company insiders | |
| Latest headline from finance.yahoo.com: Cara Q3 Earnings Snapshot |
Check out Cara Therapeutic Backtesting, Cara Therapeutic Valuation, Cara Therapeutic Correlation, Cara Therapeutic Hype Analysis, Cara Therapeutic Volatility, Cara Therapeutic History as well as Cara Therapeutic Performance. For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cara Therapeutic. If investors know Cara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cara Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.75) | Revenue Per Share 0.202 | Quarterly Revenue Growth (0.86) | Return On Assets (0.63) | Return On Equity (1.84) |
The market value of Cara Therapeutic is measured differently than its book value, which is the value of Cara that is recorded on the company's balance sheet. Investors also form their own opinion of Cara Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Cara Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cara Therapeutic's market value can be influenced by many factors that don't directly affect Cara Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cara Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cara Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cara Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.